Access the full text.
Sign up today, get DeepDyve free for 14 days.
L. Stevens (1983)
Gauging the severity of surgical sepsis.Archives of surgery, 118 10
KV Appen, C Weber, U Losert, H Schima, HJ Gurland (1996)
Microspheres based detoxification system: A new method in convective blood, 20
J. Lonergan, J. Orlowski, T. Sato, M. McHugh, M. Zborowski (1994)
Extracorporeal endotoxin removal in a canine model of septic shock.ASAIO journal, 40 3
A. Stack, R. Saladino, G. Siber, C. Thompson, M. Marra, T. Novitsky, G. Fleisher (1997)
A comparison of bactericidal/permeability-versus increasing protein variant recombinant endotoxin-neutralizing protein for the treatment of Escherichia coli sepsis in ratsCritical Care Medicine, 25
GW Duff, DM Waisman, E. Atkins (1982)
Removal of endotoxin by a polymyxin B affinity column, 30
Steffen Mitzner, J. Schneidewind, D. Falkenhagen, Fritz Loth, Horst Klinkmann (2008)
Extracorporeal endotoxin removal by immobilized polyethylenimine.Artificial organs, 17 9
J. Luce (1993)
Introduction of new technology into critical care practice: A history of HA‐1A human monoclonal antibody against endotoxinCritical Care Medicine, 21
R. Bone (1991)
The pathogenesis of sepsis.Annals of internal medicine, 115 6
D. Morrison, D. Morrison, D. Jacobs, D. Jacobs (1976)
Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides.Immunochemistry, 13 10
K. Appen, C. Weber, U. Losert, H. Schima, H. Gurland, D. Falkenhagen (1996)
Microspheres based detoxification system: a new method in convective blood purification.Artificial organs, 20 5
J. Lopes, W. Inniss (1969)
Electron Microscopy of Effect of Polymyxin on Escherichia coli LipopolysaccharideJournal of Bacteriology, 100
Corrigan Jj, Bell Bm (1971)
Endotoxin-induced intravascular coagulation: prevention with polymyxin B sulfate.Journal of Laboratory and Clinical Medicine, 77
H Aoki, T Yoshioka, K Hanasawa, Y Endo, K Matsuda, K Numa, T Oka, Y Ishii, M Kodama, H. Shoji (1988)
Fundamental study on detoxifying capacity by endotoxin adsorbing materials, 17
P. Flynn, J. Shenep, D. Stokes, D. Fairclough, W. Hildner (1987)
Polymyxin B moderates acidosis and hypotension in established, experimental gram-negative septicemia.The Journal of infectious diseases, 156 5
Gottfried El (1979)
Plasmapheresis for meningococcemia with disseminated intravascular coagulation.The New England Journal of Medicine, 300
E. Ribi, R. Anacker, R. Brown, W. Haskins, B. Malmgren, K. Milner, J. Rudbach (1966)
Reaction of Endotoxin and Surfactants I. Physical and Biological Properties of Endotoxin Treated with Sodium DeoxycholateJournal of Bacteriology, 92
S Bende, L. Bertok (1986)
Elimination of endotoxin from the blood by extracorporeal activated charcoal hemoperfusion in experimental canine endotoxin shock, 19
M. Marra, M. Thornton, C. Wilde, R. Scott (1994)
Endotoxin‐binding and -neutralizing properties of recombinant bactericidal/permeability‐increasing protein and monoclonal antibodies HA‐1A and E5Critical Care Medicine, 22
R. Bone, R. Balk, A. Fein, T. Perl, R. Wenzel, H. Reines, R. Quenzer, T. Iberti, N. MacIntyre, R. Schein (1995)
A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.Critical care medicine, 23 6
H. Aoki, Masashi Kodama, T. Tani, K. Hanasawa (1994)
Treatment of sepsis by extracorporeal elimination of endotoxin using polymyxin B-immobilized fiber.American journal of surgery, 167 4
M. Glauser, G. Zanetti, J. Baumgartner, J. Cohen (1991)
Septic shock: pathogenesisThe Lancet, 338
A. Issekutz (1983)
Removal of gram-negative endotoxin from solutions by affinity chromatography.Journal of immunological methods, 61 3
R. Goris, Theo Boekhorst, J. Nuytinck, Jules Gimbrère (1985)
Multiple-organ failure. Generalized autodestructive inflammation?Archives of surgery, 120 10
D. Weiner, N. Kuppermann, R. Saladino, C. Thompson, T. Novitsky, G. Siber, G. Fleisher (1996)
Comparison of early and late treatment with a recombinant endotoxin neutralizing protein in a rat model of Escherichia coli sepsis.Critical care medicine, 24 9
N Ihara, I Shimada, Y Nirasawa, H Ishida, M Inoue, M Honda, C Nakahara, O Hasegawa, H. Ito (1982)
Experiences with hemoperfusion and hemodialysis for the endotoxin shock, 18
K Hanasawa, T Tani, T Oka, T Yoshioka, Y Endo, M Horisawa, Y Nakane, M Kodama, K Teramoto, S. Nishiumi (1984)
Therapeutic apheresis: A Critical Look.
R. Greenman, R. Schein, MichaelA. Martin, R. Wenzel, N. Maclntyre, G. Emmanuel, H. Chmel, R. Kohler, M. McCarthy, J. Plouffe, J. Russell, E. Hollender, R. Immerman, M. Pfaller, C. Sheetz, P. Jebson, A. Houston, Dawn Rehak, P. Empson, J. Ireland, Shakti Narain, Jack Rashkin, R. Jacobs, J. Octavio, R. Coleman, V. Kenyon, B. Yangco, J. Toney, J. Edwards, M. Crislip, R. Quenzer, G. Trenholme, B. Schmitt, J. Grossman, C. Daley, H. Chambers, P. Iannini, T. Graziano, R. Dandurand, Gary Schieiter, M. Kunkel, G. Pankey, B. Mayeur, S. Abadie-Kemmerly, J. Zachery, M. Meadors, J. Coco, C. Sanders, W. George, S. Gardner, S. Finegold, G. Bernard, P. Bogden, E. Bello, A. Ellrodt, Jan Dauer, M. Riedinger, B. Meyers, T. Iberti, J. Rissing, D. Nelson, Q. Luu, G. Campbell, K. Olsen, A. Carvalho, A. Brown, H. Schmitt, Sheldon Brown, Jerome Schentag, P. Wels, P. Wing, L. Welage, R. Quintiliani, P. Chandrasekar, K. Ratzan, D. Dunn, K. Gorelick, N. Wedel, S. Saks, J. Hannigan, S. Ackerman, P. Scannon, D. Salsburg, C. Webb (1991)
A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative SepsisJAMA, 266
E. Ziegler, Charles Fisher, C. Sprung, R. Straube, J. Sadoff, G. Foulke, C. Wortel, M. Fink, R. Dellinger, N. Teng, I. Allen, H. Berger, G. Knatterud, A. Lobuglio, Craig Smith (1991)
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.The New England Journal of Medicine, 324
T Kawata, JR Bristol, JR Rose, DP Rossignol, WJ Christ, O Asano, GR Dubuc, WE Gavin, LD Hawkins, MD Lewis, PD McGuinness, MA Mullarkey, M Perez, ALC Robidoux, Y Wang, Y Kishi, S Kobayashi, A Kimura, I Hisinuma, K Ka‐tayama, I. Yamatsu (1996)
Novel therapeutic strategies in the treatment of sepsis.
K. Staubach, J. Rosenfeldt, O. Veit, H. Bruch (1997)
Extracorporeal adsorption of endotoxin.Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis, 1 1
J. Corrigan, James Kiernat (1979)
Effect of Polymyxin B Sulfate on Endotoxin Activity in a Gram-Negative Septicemia ModelPediatric Research, 13
Greenman Rl, R. Schein, M. Ma, R. Wenzel, N. MacIntyre, G. Emmanuel, H. Chmel, Kohler Rb, M. McCarthy, J. Plouffe (1991)
A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group.JAMA, 266 8
J. Nolan, J. McDevitt, G. Goldmann (1975)
Endotoxin Binding by Charged and Uncharged Resins 1Proceedings of the Society for Experimental Biology and Medicine, 149
T. Sato, J. Orlowski, M. Zborowski (1993)
Experimental study of extracorporeal perfusion for septic shock.ASAIO journal, 39 3
M. Cooperstock (1974)
Inactivation of Endotoxin by Polymyxin BAntimicrobial Agents and Chemotherapy, 6
JD Palmer, D. Rifkind (1974)
Neutralization of the hemodynamic effects of endotoxin by polymyxin B, 138
S. Minobe, T. Sato, T. Tosa, I. Chibata (1983)
Characteristics of immobilized histamine for pyrogen adsorption.Journal of chromatography, 262
H Shoji, M Minaga, Y Sakai, T Kunitomo, T Takeyama, T Tani, M. Kodama (1993)
Design and development of endotoxin detoxifying column (PMX) and its clinical application, 22
D. Rifkind, J. Palmer (1966)
Neutralization of Endotoxin Toxicity in Chick Embryos by AntibioticsJournal of Bacteriology, 92
B. Jaber, T. Barrett, M. Cendoroglo, S. Sundaram, A. King, B. Pereira (1997)
REMOVAL OF CYTOKINE-INDUCING SUBSTANCES (CIS) BY POLYMYXIN-B (PMX-B) IMMOBILIZED POLYSTYRENE-DERIVATIVE FIBERS (PDF) DURING IN VITRO HEMOPERFUSION (IVH) OF 10% HUMAN PLASMA CONTAINING STAPHYLOCOCCUS AUREVS (S. aureus)Asaio Journal, 43
T. Obayashi, H. Tamura, S. Tanaka, M. Ohki, S. Takahashi, T. Kawai (1986)
Endotoxin-inactivating activity in normal and pathological human blood samplesInfection and Immunity, 53
J. Fong (1979)
Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogsInfection and Immunity, 23
H. Togari, M. Mikawa, T. Iwanaga, N. Matsumoto, A. Kawase, M. Hagisawa, T. Ogino, Ryoji Goto, I. Watanabe, H. Kito, Y. Ogawa, Y. Wada (1983)
ENDOTOXIN CLEARANCE BY EXCHANGE BLOOD TRANSFUSION IN SEPTIC SHOCK NEONATESActa Pædiatrica, 72
C. Fisher, M. Marra, J. Palardy, C. Marchbanks, R. Scott, S. Opal (1994)
Human neutrophil bactericidal/permeability‐increasing protein reduces mortality rate from endotoxin challenge: A placebo‐controlled studyCritical Care Medicine, 22
D. Rifkind, R. Hill (1967)
Neutralization of the Shwartzman reactions by polymyxins B.Journal of immunology, 99 3
D. Kett, A. Quartin, C. Sprung, C. Fisher, S. Heard, J. Zimmerman, T. Albertson, L. Eidelman, R. Schein (1994)
An evaluation of the hemodynamic effects of HA‐1A human monoclonal antibodyCritical Care Medicine, 22
M Niwa, M Umeda, K. Ohashi (1982)
Inactivation and immobilization of endotoxin: A novel endotoxin binding substances, polymyxin sepharose, 35
J. Cohen, Mohammed Aslam, C. Pusey, C. Ryan (1987)
Protection from endotoxemia: a rat model of plasmapheresis and specific adsorption with polymyxin B.The Journal of infectious diseases, 155 4
M. Kodama, T. Tani, K. Hanasawa (1997)
EXTRACORPOREAL REMOVAL OF ENDOTOXIN IN THE SEPTIC PATIENTS BYTORAYMYXINR‐CLINICALRESULTSINAPHASE II AND III INJAPAN: 22Shock, 7
A. Suffredini, R. Fromm, M. Parker, M. Brenner, J. Kovacs, R. Wesley, J. Parrillo (1989)
The cardiovascular response of normal humans to the administration of endotoxin.The New England journal of medicine, 321 5
BL Jaber, TW Barrett, M Cendoroglo, S Sundaram, AJ King, BJG. Pereira (1997)
Endotoxin removal by polymyxin B (PMX‐B) immobilized polystyrene‐derived fibers (PDF) during in vitro hemoperfusion (IVH) of 10% human plasma. Abstract, 43rd Annual Conference, 43
J Bader, M. Teuber (1973)
Binding to the O‐antigenic lipopolysaccharide of Salmonella lyphimurium, 28c
R. Christensen, H. Hill, H. Anstall, G. Rothstein (1984)
Exchange transfusion as an alternative to granulocyte concentrate administration in neonates with bacterial sepsis and profound neutropeniaJournal of Clinical Apheresis, 2
BL Jaber, TW Barrett, M Cendoroglo, S Sundaram, AJ King, BJG. Pereira (1997)
Removal of cytokine‐inducing substances (CIS) by polymyxin B (PMX‐B) immobilized polystyrene‐derivative fibers (PDF) during in vitro hemoperfusion (IVH) of 10% human plasma containing Staphylococcus aureus (S. aureus). Abstract, 43rd Annual Conference, 43
David LaPorte, Ken Rosenthal, Dan Storm (1977)
Inhibition of Escherichia coli growth and respiration by polymyxin B covalently attached to agarose beads.Biochemistry, 16 8
J. Parrillo (1993)
Pathogenetic mechanisms of septic shock.The New England journal of medicine, 328 20
J. Parrillo, M. Parker, C. Natanson, A. Suffredini, R. Danner, R. Cunnion, F. Ognibene (1990)
Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy.Annals of internal medicine, 113 3
Abstract: We have developed an extracorporeal hemoad‐sorption cartridge, the PMX cartridge, to eliminate endotoxin from peripheral blood circulation. As an adsorbent, a polymyxin B covalently immobilized fiber (PMX‐F) was developed. After the optimization of the condition of immobilization, fixed polymyxin B maintained its ability to adsorb endotoxin and its bactericidal activity. PMX‐F could detoxify many kinds of endotoxin in vitro. Fixed polymyxin B was estimated to interact with the lipid A portion of endotoxin. Utilization of fibrous adsorbents enabled us to design the PMX cartridge with a large surface area and low blood pressure drop in the blood flow compartment and to apply it safely to the direct hemoperfusion procedure. In Japan, the PMX cartridge is now being clinically applied as one of the therapeutical interventions for sepsis, septic shock, and septic multiple organ failure. In multicenter clinical studies, the blood endotoxin level has been significantly decreased. Accompanied with elimination of endotoxin, hemodynamic abnormalities such as low blood pressure and low systemic vascular resistance were significantly improved. In more recent multicenter studies, the average number of failed organs; severity of illness score, such as Goris score; and vasopressor dosage were significantly decreased. The PMX cartridge is expected to be effective in the intervention for the treatment of septic shock. Endotoxin may be one of the therapeutical targets for the treatment of sepsis.
Therapeutic Apheresis and Dialysis – Wiley
Published: Feb 1, 1998
Keywords: ; ;
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.